istock-625888460mraoraor
mraoraor / iStockphoto.com
7 February 2018Americas

Teva goes to war with Eli Lilly over migraine breakthrough

Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
1 October 2018   Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.

More on this story

Big Pharma
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
1 October 2018   Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.

More on this story

Big Pharma
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
1 October 2018   Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.